Summit Therapeutics
SMMT
54 hedge funds and large institutions have $23.3M invested in Summit Therapeutics in 2021 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 29 increasing their positions, 13 reducing their positions, and 8 closing their positions.
395% more call options, than puts
Call options by funds: $638K | Put options by funds: $129K
123% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 13
0.05% less ownership
Funds ownership: 11.37% → 11.32% (-0.05%)
7% less funds holding
Funds holding: 58 → 54 (-4)
23% less capital invested
Capital invested by funds: $30.4M → $23.3M (-$7.12M)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$1.15M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$889K |
| 3 |
BlackRock
New York
|
+$757K |
| 4 |
Russell Investments Group
London,
United Kingdom
|
+$627K |
| 5 |
State Street
Boston,
Massachusetts
|
+$570K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$4.01M |
| 2 |
Renaissance Technologies
New York
|
-$936K |
| 3 |
Fidelity International
Hamilton,
Bermuda
|
-$777K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$184K |
| 5 |
California State Teachers Retirement System (CalSTRS)
West Sacramento,
California
|
-$122K |
SMMT Hedge Fund Activity: Q3 2021 in Review
54 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q3 2021, worth a combined $23.3M — down 23% from $30.4M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of SMMT and 4 opened new positions — a net loss of 4 holders — while 13 trimmed existing stakes and 29 added.
The largest buyer was Northern Trust, adding an estimated $1.15M. The largest seller was Polar Capital Holdings, cutting an estimated $4.01M.
- 54 institutional investors held Summit Therapeutics (SMMT) as of Q3 2021, down from 58 in Q2 2021.
- Funds reported $23.3M of Summit Therapeutics stock for Q3 2021, down 23% quarter-over-quarter.
- 4 funds opened new Summit Therapeutics positions in Q3 2021 and 8 closed out, a net change of -4 holders.
- The largest Summit Therapeutics buyer in Q3 2021 was Northern Trust, an estimated $1.15M added.
- The largest Summit Therapeutics seller in Q3 2021 was Polar Capital Holdings, an estimated $4.01M sold.
Based on aggregated 13F filings for Q3 2021.